Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | ASAH1 | Q13510 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110389 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL24110380 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL2184004 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL29145166 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL24110493 | 0.79 | KMT2A (0.46) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL24109893 | 0.79 | KMT2A (0.46) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL24110390 | 0.79 | KMT2A (0.46) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL16596879 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL24110584 | 0.78 | MTNR1A (0.46) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL24110473 | 0.78 | MTNR1A (0.46) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | SMN1; SMN2 766/4885ALDH1A1 1852/4885HPGD 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.